Final answer:
The correct drug profile characteristic of current open-angle glaucoma therapy is the Rho kinase antagonist, which works by increasing aqueous humor outflow to lower intraocular pressure.
Step-by-step explanation:
The drug profile characteristic of current open-angle glaucoma therapy is d) Rho kinase antagonist. In current treatment protocols, Rho kinase antagonists are utilized for their ability to reduce intraocular pressure, which is crucial in managing open-angle glaucoma. These drugs act by increasing the outflow of aqueous humor through the trabecular meshwork, thereby reducing intraocular pressure. Both alpha-2 adrenergic receptor agonists and prostaglandin F2α (PGF2α) analogs are also used as glaucoma medications, but they work differently. Alpha-2 agonists decrease aqueous humor production and increase uveoscleral outflow while PGF2α analogs primarily increase uveoscleral outflow.